These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
408 related articles for article (PubMed ID: 17919428)
1. [Analysis of lymphocyte populations in psoriatic plaques following inhibition of tumor necrosis factor alpha with etanercept]. Mahiques L; Pitarch G; Sánchez-Carazo JL; Pérez-Ferriols A; Soriano CJ; Alegre V Actas Dermosifiliogr; 2007 Oct; 98(8):539-44. PubMed ID: 17919428 [TBL] [Abstract][Full Text] [Related]
2. Treatment of erythrodermic psoriasis with etanercept. Esposito M; Mazzotta A; de Felice C; Papoutsaki M; Chimenti S Br J Dermatol; 2006 Jul; 155(1):156-9. PubMed ID: 16792768 [TBL] [Abstract][Full Text] [Related]
3. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Strober B; Teller C; Yamauchi P; Miller JL; Hooper M; Yang YC; Dann F Br J Dermatol; 2008 Aug; 159(2):322-30. PubMed ID: 18503600 [TBL] [Abstract][Full Text] [Related]
4. Etanercept treatment for children and adolescents with plaque psoriasis. Paller AS; Siegfried EC; Langley RG; Gottlieb AB; Pariser D; Landells I; Hebert AA; Eichenfield LF; Patel V; Creamer K; Jahreis A; N Engl J Med; 2008 Jan; 358(3):241-51. PubMed ID: 18199863 [TBL] [Abstract][Full Text] [Related]
5. CTACK /CCL27 expression in psoriatic skin and its modification after administration of etanercept. Campanati A; Goteri G; Simonetti O; Ganzetti G; Giuliodori K; Stramazzotti D; Morichetti D; Bernardini ML; Mannello B; Fabris G; Offidani A Br J Dermatol; 2007 Dec; 157(6):1155-60. PubMed ID: 17916208 [TBL] [Abstract][Full Text] [Related]
6. [Clinical experience with etanercept in the treatment of psoriasis]. Martín B; Sánchez-Carazo JL; Pérez-Ferriols A; Laguna C; Oliver V; Alegre V Actas Dermosifiliogr; 2008 Sep; 99(7):540-5. PubMed ID: 18682167 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study. Mazzotta A; Esposito M; Costanzo A; Chimenti S Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of etanercept in children and adolescents aged > or = 8 years with severe plaque psoriasis. Landells I; Paller AS; Pariser D; Kricorian G; Foehl J; Molta C; Freundlich B Eur J Dermatol; 2010; 20(3):323-8. PubMed ID: 20185386 [TBL] [Abstract][Full Text] [Related]
9. Two years of experience with etanercept in recalcitrant psoriasis. Ahmad K; Rogers S Br J Dermatol; 2007 May; 156(5):1010-4. PubMed ID: 17408393 [TBL] [Abstract][Full Text] [Related]
10. Effects of etanercept on urine neopterin levels in patients with psoriasis in a controlled, open-label study. Koc E; Tunca M; Akgul EO; Akar A; Kurt Y; Kurumlu Z; Erbil K; Kilic S J Dermatol; 2009 Apr; 36(4):191-6. PubMed ID: 19348656 [TBL] [Abstract][Full Text] [Related]
11. [Long-term safety and efficacy of etanercept in the treatment of psoriasis]. Zaragoza V; Pérez A; Sánchez JL; Oliver V; Martínez L; Alegre V Actas Dermosifiliogr; 2010; 101(1):47-53. PubMed ID: 20109392 [TBL] [Abstract][Full Text] [Related]
12. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Papp KA; Tyring S; Lahfa M; Prinz J; Griffiths CE; Nakanishi AM; Zitnik R; van de Kerkhof PC; Melvin L; Br J Dermatol; 2005 Jun; 152(6):1304-12. PubMed ID: 15948997 [TBL] [Abstract][Full Text] [Related]
13. Treatment with 311-nm ultraviolet B accelerates and improves the clearance of psoriatic lesions in patients treated with etanercept. Wolf P; Hofer A; Legat FJ; Bretterklieber A; Weger W; Salmhofer W; Kerl H Br J Dermatol; 2009 Jan; 160(1):186-9. PubMed ID: 19067710 [TBL] [Abstract][Full Text] [Related]
14. Etanercept in the treatment and retreatment of psoriasis in daily clinical practice. Barrera MV; Habicheyn S; Mendiola MV; Herrera Ceballos E Eur J Dermatol; 2008; 18(6):683-7. PubMed ID: 19049936 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. Gordon K; Korman N; Frankel E; Wang H; Jahreis A; Zitnik R; Chang T J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S101-11. PubMed ID: 16488320 [TBL] [Abstract][Full Text] [Related]
16. Initial experience with routine administration of etanercept in psoriasis. de Groot M; Appelman M; Spuls PI; de Rie MA; Bos JD Br J Dermatol; 2006 Oct; 155(4):808-14. PubMed ID: 16965432 [TBL] [Abstract][Full Text] [Related]
17. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Krueger GG; Langley RG; Finlay AY; Griffiths CE; Woolley JM; Lalla D; Jahreis A Br J Dermatol; 2005 Dec; 153(6):1192-9. PubMed ID: 16307657 [TBL] [Abstract][Full Text] [Related]
18. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. van de Kerkhof PC; Segaert S; Lahfa M; Luger TA; Karolyi Z; Kaszuba A; Leigheb G; Camacho FM; Forsea D; Zang C; Boussuge MP; Paolozzi L; Wajdula J Br J Dermatol; 2008 Nov; 159(5):1177-85. PubMed ID: 18673365 [TBL] [Abstract][Full Text] [Related]
20. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Tyring S; Gordon KB; Poulin Y; Langley RG; Gottlieb AB; Dunn M; Jahreis A Arch Dermatol; 2007 Jun; 143(6):719-26. PubMed ID: 17576937 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]